Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Axim Biotechnologies Inc (OP: AXIM ) 0.0040 +0.0006 (+17.65%) Streaming Delayed Price Updated: 3:46 PM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 730,255 Open 0.0039 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0034 Today's Range 0.0036 - 0.0042 52wk Range 0.0020 - 0.0220 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News AXIM Biotechnologies Receives Medical Device Manufacturing License May 29, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 March 27, 2024 Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s Via TheNewswire.com Performance YTD -80.39% -80.39% 1 Month +33.33% +33.33% 3 Month -63.64% -63.64% 6 Month -57.89% -57.89% 1 Year -75.76% -75.76% More News Read More VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 March 27, 2024 Via NewMediaWire AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation February 20, 2024 Via NewMediaWire AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation February 20, 2024 Via TheNewswire.com AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production December 20, 2023 Via NewMediaWire AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease September 12, 2023 From AXIM Biotechnologies, Inc. Via Business Wire AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test August 01, 2023 From AXIM Biotechnologies, Inc. Via Business Wire Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide July 12, 2023 Via NewMediaWire AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide July 12, 2023 Via NewMediaWire AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch May 24, 2023 Via NewMediaWire AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit May 23, 2023 Via NewMediaWire Exposures Product Safety AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays April 11, 2023 Via NewMediaWire AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing March 14, 2023 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion March 14, 2023 Via NewMediaWire Topics Cannabis Exposures Cannabis AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance January 17, 2023 Via NewMediaWire Topics Intellectual Property Exposures Intellectual Property AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent December 13, 2022 From AXIM BIOTECHNOLOGIES, INC Via GlobeNewswire AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions December 06, 2022 From AXIM BIOTECHNOLOGIES, INC Via GlobeNewswire AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch October 04, 2022 From AXIM BIOTECHNOLOGIES, INC Via GlobeNewswire AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022 September 29, 2022 From AXIM BIOTECHNOLOGIES, INC Via GlobeNewswire AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season July 26, 2022 From AXIM BIOTECHNOLOGIES, INC Via GlobeNewswire Will This Dry Eye Rapid Test Prove To Be A Rapid Success? July 07, 2022 Via Benzinga Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022 May 19, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
